208 related articles for article (PubMed ID: 34867972)
1. Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer.
Zhang Z; Wu P; Zhang C; Luo Y; Zhang G; Zeng Q; Wang L; Yang Z; Sun N; He J
Front Immunol; 2021; 12():745769. PubMed ID: 34867972
[TBL] [Abstract][Full Text] [Related]
2. An immune checkpoint-based signature predicts prognosis and chemotherapy response for patients with small cell lung cancer.
Wang L; Wu P; Shen Z; Yu Q; Zhang Y; Ye F; Chen K; Zhao J
Int Immunopharmacol; 2023 Apr; 117():109827. PubMed ID: 36989973
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analyses of N
Luo Y; Zhang Z; Zheng B; Wu P; Zhang G; Wang L; Zeng Q; Yang Z; Xue L; Zeng H; Tan F; Xue Q; Gao S; Sun N; He J
Cancer Sci; 2022 Dec; 113(12):4289-4299. PubMed ID: 36047973
[TBL] [Abstract][Full Text] [Related]
4. m
Zhang Z; Zhang C; Luo Y; Wu P; Zhang G; Zeng Q; Wang L; Yang Z; Xue L; Zheng B; Zeng H; Tan F; Xue Q; Gao S; Sun N; He J
BMC Med; 2021 Nov; 19(1):284. PubMed ID: 34802443
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive molecular analyses of a TNF family-based signature with regard to prognosis, immune features, and biomarkers for immunotherapy in lung adenocarcinoma.
Zhang C; Zhang G; Sun N; Zhang Z; Zhang Z; Luo Y; Che Y; Xue Q; He J
EBioMedicine; 2020 Sep; 59():102959. PubMed ID: 32853987
[TBL] [Abstract][Full Text] [Related]
6. Development and Validation of a TNF Family-Based Signature for Predicting Prognosis, Tumor Immune Characteristics, and Immunotherapy Response in Colorectal Cancer Patients.
Xiao Z; Nie K; Han T; Cheng L; Zhang Z; Peng W; Shi D
J Immunol Res; 2021; 2021():6439975. PubMed ID: 34541005
[TBL] [Abstract][Full Text] [Related]
7. A microRNA signature predicts survival in early stage small-cell lung cancer treated with surgery and adjuvant chemotherapy.
Bi N; Cao J; Song Y; Shen J; Liu W; Fan J; He J; Shi Y; Zhang X; Lu N; Zhan Q; Wang L
PLoS One; 2014; 9(3):e91388. PubMed ID: 24637927
[TBL] [Abstract][Full Text] [Related]
8. The identification of a two-gene prognostic model based on cisplatin resistance-related ceRNA network in small cell lung cancer.
Zhang Y; Zhu Q; Qi J; Fu M; Xu A; Wang W; Wang H; Nie J; Hong B
BMC Med Genomics; 2023 May; 16(1):103. PubMed ID: 37189142
[TBL] [Abstract][Full Text] [Related]
9. The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.
Tian WJ; Liu SS; Li BR
Technol Cancer Res Treat; 2020; 19():1533033820977504. PubMed ID: 33256552
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of a TNF family based-signature in diffuse gliomas with regard to prognosis and immune significance.
Wang QW; Lin WW; Zhu YJ
Cell Commun Signal; 2022 Jan; 20(1):6. PubMed ID: 35000592
[TBL] [Abstract][Full Text] [Related]
11. Immune Cell Infiltration May Be a Key Determinant of Long-Term Survival in Small Cell Lung Cancer.
Muppa P; Parrilha Terra SBS; Sharma A; Mansfield AS; Aubry MC; Bhinge K; Asiedu MK; de Andrade M; Janaki N; Murphy SJ; Nasir A; Van Keulen V; Vasmatzis G; Wigle DA; Yang P; Yi ES; Peikert T; Kosari F
J Thorac Oncol; 2019 Jul; 14(7):1286-1295. PubMed ID: 31078775
[TBL] [Abstract][Full Text] [Related]
12. A highly expressed mRNA signature for predicting survival in patients with stage I/II non-small-cell lung cancer after operation.
Ma N; Si L; Yang M; Li M; He Z
Sci Rep; 2021 Mar; 11(1):5855. PubMed ID: 33712694
[TBL] [Abstract][Full Text] [Related]
13. m
Zhang Z; Zhang C; Yang Z; Zhang G; Wu P; Luo Y; Zeng Q; Wang L; Xue Q; Zhang Y; Sun N; He J
J Hematol Oncol; 2021 Nov; 14(1):190. PubMed ID: 34758859
[TBL] [Abstract][Full Text] [Related]
14. [Correlations between genetic variations of glutathione synthetase gene and the response to platinum-based chemotherapy and prognosis of small cell lung cancer patients].
Feng T; Li HM; Yuan P; Yu DK; Ma F; Tan WW; Du ZL; Yang J; Huang Y; Lin DX; Xu BH; Tan W
Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):115-120. PubMed ID: 28219206
[No Abstract] [Full Text] [Related]
15. Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer.
Zhang X; Shi X; Zhao H; Jia X; Yang Y
Biomed Res Int; 2021; 2021():8864436. PubMed ID: 33860055
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of nomograms for predicting survival of elderly patients with stage I small-cell lung cancer.
Yang Y; Sun S; Wang Y; Xiong F; Xiao Y; Huang J
Bosn J Basic Med Sci; 2021 Oct; 21(5):632-641. PubMed ID: 33577444
[TBL] [Abstract][Full Text] [Related]
17. FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.
Jiang M; Wu C; Zhang L; Sun C; Wang H; Xu Y; Sun H; Zhu J; Zhao W; Fang Q; Yu J; Chen P; Wu S; Zheng Z; He Y; Zhou C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006632
[TBL] [Abstract][Full Text] [Related]
18. Identification of a survival-related signature for sarcoma patients through integrated transcriptomic and proteomic profiling analyses.
Zhang B; Yang L; Wang X; Fu D
Gene; 2021 Jan; 764():145105. PubMed ID: 32882333
[TBL] [Abstract][Full Text] [Related]
19. Immune signature of T follicular helper cells predicts clinical prognostic and therapeutic impact in lung squamous cell carcinoma.
Xu F; Zhang H; Chen J; Lin L; Chen Y
Int Immunopharmacol; 2020 Apr; 81():105932. PubMed ID: 31836430
[TBL] [Abstract][Full Text] [Related]
20. A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma.
Zou X; Hu Z; Huang C; Chang J
Med Sci Monit; 2020 Jul; 26():e924269. PubMed ID: 32613949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
